Intercure Ltd Quick Ratio (INCR) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Intercure Ltd   (NASDAQ: INCR)

Intercure Ltd 's Quick Ratio

INCR's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2025, Quick Ratio deteriorated to 0.22 a new company low.

Within Major Pharmaceutical Preparations industry 464 other companies have achieved higher Quick Ratio than Intercure Ltd in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from 2961 to 4040.

Explain Quick Ratio?
How much Cash & cash equivalents INCR´s has?
What are INCR´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

INCR Quick Ratio (Dec 31 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2024)
Q4
Y / Y Current Liabilities Change 245.36 % 245.36 % 245.36 % 245.36 % -62.69 %
Y / Y Cash & cash equivalent Change 116.74 % 116.74 % 116.74 % 116.74 % -78.8 %
Quick Ratio MRQ 0.22 0.22 0.22 0.22 0.35
INCR's Total Ranking # 4040 # 2961 # # #
Seq. Current Liabilities Change 0 % 0 % 0 % 245.36 % 0 %
Seq. Cash & cash equivalent Change 0 % 0 % 0 % 116.74 % 0 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 465
Healthcare Sector # 909
Overall Market # 4040


Quick Ratio Statistics
High Average Low
1.27 0.6 0.22
(Dec 31 2020)   (Dec 31 2025)




Financial Statements
Intercure Ltd 's Current Liabilities $ 214 Millions Visit INCR's Balance sheet
Intercure Ltd 's Cash & cash equivalent $ 46 Millions Visit INCR's Balance sheet
Source of INCR's Sales Visit INCR's Sales by Geography


Cumulative Intercure Ltd 's Quick Ratio

INCR's Quick Ratio for the trailling 12 Months

INCR Quick Ratio

 (Dec 31 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth 245.36 % 100.01 % 56.7 % 13.46 % -29.73 %
Y / Y Cash & cash equivalent TTM Growth 116.74 % -2.79 % -21.01 % -37.9 % -53.61 %
Quick Ratio TTM 0.22 0.23 0.25 0.28 0.35
Total Ranking TTM # 3826 # 3735 # # #
Seq. Current Liabilities TTM Growth 21.6 % 27.55 % 38.02 % 61.34 % -29.58 %
Seq. Cash & cash equivalent TTM Growth 15.56 % 18.43 % 22.59 % 29.18 % -48.17 %

Quick ratio ranking by company, industry and sector >> Back to INCR Financial Strength Comparisons >> Go to Compare INCR Quick Ratio to its Competitors

On the trailing twelve months basis Due to unchanged in Current Liabilities in the Q4 2025 to $214.37 millions, cumulative Quick Ratio decreased to 0.22 below the Intercure Ltd average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 441 other companies have achieved higher Quick Ratio than Intercure Ltd . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from 3735 to 3826.

Explain Quick Ratio?
How much Cash & cash equivalents INCR´s has?
What are INCR´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 442
Healthcare Sector # 905
Within the Market # 3826


trailing twelve months Quick Ratio Statistics
High Average Low
1.01 0.5 0.22
(Dec 31 2021)   (Dec 31 2025)




Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2025 MRQ Cash & cash equivalentDec 31 2025 MRQ Current Liabilities
Aurinia Pharmaceuticals Inc   0.59 $ 80.160  Millions$ 135.252  Millions
Promis Neurosciences inc   0.59 $ 6.150  Millions$ 10.441  Millions
Xencor Inc  0.58 $ 55.659  Millions$ 95.907  Millions
Ascendis Pharma A  0.58 $ 691.961  Millions$ 1,197.718  Millions
Earth Science Tech Inc   0.58 $ 1.811  Millions$ 3.146  Millions
Johnson and Johnson  0.57 $ 20,102.000  Millions$ 35,002.000  Millions
Ainos Inc   0.57 $ 0.417  Millions$ 0.729  Millions
Blue Water Vaccines Inc  0.57 $ 5.221  Millions$ 9.165  Millions
Esperion Therapeutics Inc   0.56 $ 167.852  Millions$ 300.810  Millions
Biofrontera Inc   0.54 $ 6.392  Millions$ 11.895  Millions
Bioxcel Therapeutics Inc   0.53 $ 28.415  Millions$ 53.926  Millions
Apollomics Inc   0.52 $ 3.276  Millions$ 6.326  Millions
Merck and Co Inc   0.51 $ 14,565.000  Millions$ 28,327.000  Millions
Jupiter Neurosciences Inc   0.51 $ 3.789  Millions$ 7.375  Millions
Tuhura Biosciences Inc   0.51 $ 3.620  Millions$ 7.048  Millions
Immunic Inc   0.51 $ 15.483  Millions$ 30.618  Millions
Indivior Pharmaceuticals Inc   0.50 $ 212.000  Millions$ 424.000  Millions
Phibro Animal Health Corporation  0.50 $ 77.039  Millions$ 154.451  Millions
Assertio Holdings inc   0.49 $ 63.405  Millions$ 128.107  Millions
Aytu Biopharma Inc  0.49 $ 30.952  Millions$ 63.064  Millions
Heron Therapeutics Inc   0.49 $ 46.631  Millions$ 96.098  Millions
Clene Inc   0.48 $ 5.189  Millions$ 10.776  Millions
Akari Therapeutics Plc  0.47 $ 5.203  Millions$ 11.019  Millions
Elanco Animal Health Incorporated  0.46 $ 545.000  Millions$ 1,181.000  Millions
Quantum Biopharma Ltd   0.46 $ 1.905  Millions$ 4.182  Millions
Bristol myers Squibb Company  0.44 $ 10,673.000  Millions$ 24,396.000  Millions
Grifols Sa  0.42 $ 943.040  Millions$ 2,261.280  Millions
Novartis Ag  0.41 $ 11,640.000  Millions$ 28,072.000  Millions
Eli Lilly And Company  0.41 $ 7,268.000  Millions$ 17,846.000  Millions
Aeon Biopharma inc   0.40 $ 3.006  Millions$ 7.467  Millions

Date modified: 2026-07-07T11:48:09+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.